| Market Capitalization (Millions $) |
1,659 |
| Shares
Outstanding (Millions) |
16 |
| Employees |
110 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-138 |
| Cash Flow (TTM) (Millions $) |
-25 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Inhibrx Inc is a biopharmaceutical company that specializes in the development of innovative antibody therapeutics. The company focuses on creating therapeutics for the treatment of various diseases, including cancer, immunological disorders, and rare genetic diseases.
Inhibrx utilizes a proprietary platform called single-domain antibody (sdAb) technology, which allows for the creation of highly specific and potent antibodies. These sdAbs have the ability to target and bind to specific disease-causing proteins, known as antigens, with high affinity.
The company's sdAb-based therapeutics have the potential to provide significant benefits over traditional antibody therapies, including improved tissue penetration, increased stability, and enhanced safety profiles. Inhibrx is dedicated to advancing these innovative treatments through rigorous preclinical and clinical development.
Inhibrx collaborates with pharmaceutical companies, research institutions, and healthcare organizations to accelerate the development and commercialization of its novel antibody therapeutics. The company is committed to making a meaningful impact on patients' lives by providing new treatment options for a range of debilitating and life-threatening diseases.
Company Address: 11025 N. Torrey Pines Road La Jolla 92037 CA
Company Phone Number: 795-4220 Stock Exchange / Ticker: NASDAQ INBX
|
